STOCK TITAN

Aura Biosciences, Inc. - AURA STOCK NEWS

Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.

Aura Biosciences, Inc. (symbol: AURA) is a clinical-stage biotechnology company revolutionizing cancer treatment through the development of precision immunotherapies. The company's pioneering approach, known as molecular surgery, targets and destroys cancer cells selectively while sparing the surrounding healthy tissue. This method holds promise in treating various cancers, particularly those that are challenging to manage with current therapies.

Aura Biosciences' lead program focuses on ocular melanoma (OM), also known as choroidal or uveal melanoma. This innovative therapy aims to eliminate cancer cells in the eye as a first-line treatment, with the potential to preserve patients' vision. By addressing the cancer early, Aura Biosciences seeks to prevent the disease from progressing and metastasizing to other organs such as the liver, where it often becomes fatal.

In addition to OM, the company's lead candidate, bel-sar, is in early-stage clinical development for bladder cancer and other ocular oncology indications. This first-in-class, non-radioactive treatment offers a novel approach to precisely target and eradicate cancer cells.

Aura Biosciences is also exploring treatments for cancers of the ocular surface, affecting approximately 35,000 patients in the United States and Europe annually. Positive preclinical data for bel-sar in this indication were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.

Recently, the company strengthened its leadership team with the appointment of Conor Kilroy as General Counsel and Secretary, further solidifying its strategic vision and operational capabilities.

Operating exclusively in the United States, Aura Biosciences is committed to advancing its clinical programs and bringing transformative cancer therapies to patients worldwide.

Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, announced participation in the Jefferies Global Healthcare Conference. CEO Elisabet de los Pinos will present on June 6, 2024, at 12:30 p.m. ET. The presentation will be webcast live and available on Aura Biosciences' website, with a replay accessible for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Aura Biosciences will host a virtual KOL event titled “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024, at 2:00 PM ET.

Experts including Dr. Carol Shields, Dr. Hakan Demirci, and Dr. Mandeep Sagoo will discuss the unmet medical needs and current treatments for ocular cancers like primary uveal melanoma and metastases to the choroid. The event will spotlight Aura's lead candidate, bel-sar, which is in a Phase 3 trial for early-stage uveal melanoma.

The event will feature a panel discussion moderated by Chris Howerton and will include a live Q&A session. The webcast will be available on Aura's website and archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
conferences
-
Rhea-AI Summary

Aura Biosciences, Inc. (NASDAQ: AURA) reported financial results for Q1 2024, highlighting progress in ocular and urologic oncology programs. The company is enrolling in a Phase 3 trial for small choroidal melanoma, with positive pipeline developments in bel-sar treatments for various ocular cancers and bladder cancer. Aura has a strong cash position expected to fund operations until H2 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
Rhea-AI Summary

Aura Biosciences, Inc. (NASDAQ: AURA) will have its CEO participating in upcoming investor conferences to discuss the company's precision immunotherapies for solid tumors. The webcasts will be available on the company's website for 90 days after the presentation date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
-
Rhea-AI Summary
Aura Biosciences, Inc. (NASDAQ: AURA) is enrolling patients in a global Phase 3 CoMpass trial for small choroidal melanoma and indeterminate lesions, with data expected in mid-2024. The company has a strong cash position until the second half of 2026. Bel-sar, a potential vision-and-organ sparing therapy, is being expanded into bladder cancer, addressing major unmet medical needs in ocular oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
-
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) announced CEO Elisabet de los Pinos will participate in investor conferences. The company develops virus-like drug conjugate therapies for oncology. Webcasts of the conferences will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) has announced the dosing of the first patient in the global Phase 3 CoMpass trial for bel-sar, a novel VDC therapy for early-stage choroidal melanoma. The trial, with an FDA SPA agreement, aims to evaluate the safety and efficacy of bel-sar as a first-line treatment for this rare disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
-
Rhea-AI Summary
Aura Biosciences, Inc. (NASDAQ: AURA) received FDA agreement under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial, presenting positive clinical efficacy updates of Bel-sar for early-stage choroidal melanoma. The company also raised gross proceeds of $99.0 million in an underwritten public offering. Positive clinical efficacy updates and financial results for the third quarter were highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.54%
Tags
-
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) CEO to participate in investor conferences, including Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Live webcasts and replays available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
Rhea-AI Summary
Aura Biosciences, Inc. (Nasdaq: AURA) has announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at $9.00 per share. The gross proceeds from the offering are expected to be $99.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.55%
Tags

FAQ

What is Aura Biosciences, Inc. known for?

Aura Biosciences, Inc. is known for developing precision immunotherapies to selectively target and destroy cancer cells without harming surrounding tissue.

What is molecular surgery?

Molecular surgery is an innovative approach pioneered by Aura Biosciences to selectively target and eliminate cancer cells while preserving healthy tissue.

What is the lead program of Aura Biosciences?

The lead program focuses on treating ocular melanoma (OM) by eliminating cancer cells in the eye and potentially preserving patients' vision.

What is bel-sar?

Bel-sar is Aura Biosciences' lead candidate in late-stage clinical development for ocular melanoma and early-stage development for bladder cancer.

What recent corporate event has Aura Biosciences announced?

Aura Biosciences recently appointed Conor Kilroy as General Counsel and Secretary to strengthen its leadership team.

What is the significance of Aura Biosciences' approach to cancer treatment?

Aura Biosciences' approach aims to treat cancer early by selectively destroying cancer cells, potentially transforming the management of hard-to-treat cancers.

In which regions does Aura Biosciences operate?

Aura Biosciences operates exclusively in the United States.

What are cancers of the ocular surface?

Cancers of the ocular surface are a potential ocular oncology indication affecting around 35,000 patients annually in the US and Europe, which Aura Biosciences is exploring.

What is the goal of Aura Biosciences' ocular melanoma therapy?

The goal is to treat small ocular melanomas early to prevent progression and metastasis, preserving patients' vision and potentially saving lives.

Where can I find the latest news about Aura Biosciences?

The latest news and updates about Aura Biosciences can be found on the StockTitan website and other financial news platforms.

Aura Biosciences, Inc.

Nasdaq:AURA

AURA Rankings

AURA Stock Data

429.54M
49.54M
7.53%
79.16%
5.82%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BOSTON